OliX Pharmaceuticals Inc (KOSDAQ:226950), a pharmaceutical company based in South Korea, said on Wednesday that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to develop its RNAi therapeutic OLX10212 for the treatment of age-related macular degeneration (AMD).
OLX10212 targets inflammation pathways that play a key role in the development of geographic atrophy (GA) and neovascular AMD. The primary objective of the phase 1 study is to evaluate the safety and tolerability of OLX10212 in patients with AMD.
With the FDA approval of the IND application for OLX10212, OliX has initiated clinical trials for two investigational therapeutic programmes in the US. In June 2022 the company completed patient enrolment for the Phase 2a clinical trial of OLX10010, for the treatment of hypertrophic scarring.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT